JPWO2020118066A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020118066A5 JPWO2020118066A5 JP2021513314A JP2021513314A JPWO2020118066A5 JP WO2020118066 A5 JPWO2020118066 A5 JP WO2020118066A5 JP 2021513314 A JP2021513314 A JP 2021513314A JP 2021513314 A JP2021513314 A JP 2021513314A JP WO2020118066 A5 JPWO2020118066 A5 JP WO2020118066A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- alkyl
- kras
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 78
- 230000002401 inhibitory effect Effects 0.000 claims 48
- 239000003112 inhibitor Substances 0.000 claims 45
- 125000000217 alkyl group Chemical group 0.000 claims 35
- -1 -C(O) N(R ) 2 Chemical group 0.000 claims 32
- 102200006538 KRAS G12C Human genes 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 102100017818 PTPN11 Human genes 0.000 claims 21
- 101710018405 PTPN11 Proteins 0.000 claims 21
- 125000004404 heteroalkyl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims 18
- 125000001188 haloalkyl group Chemical group 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 17
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 210000004027 cells Anatomy 0.000 claims 10
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 8
- 208000009956 Adenocarcinoma Diseases 0.000 claims 7
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 206010025310 Other lymphomas Diseases 0.000 claims 7
- 206010039491 Sarcoma Diseases 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 201000009030 carcinoma Diseases 0.000 claims 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 206010024612 Lipoma Diseases 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000005418 aryl aryl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 230000035945 sensitivity Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- 206010016629 Fibroma Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atoms Chemical group C* 0.000 claims 3
- 201000008808 fibrosarcoma Diseases 0.000 claims 3
- 201000011066 hemangioma Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000002458 Carcinoid Tumor Diseases 0.000 claims 2
- 206010007275 Carcinoid tumour Diseases 0.000 claims 2
- 208000002927 Hamartoma Diseases 0.000 claims 2
- 206010024190 Leiomyosarcomas Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010027191 Meningioma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010043276 Teratoma Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002489 hematologic Effects 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 201000004404 neurofibroma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 230000004083 survival Effects 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- KEFBAMRFXYKOBI-UHFFFAOYSA-N 1,4$l^{2}-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CC[N]CC1 KEFBAMRFXYKOBI-UHFFFAOYSA-N 0.000 claims 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 claims 1
- 241000321096 Adenoides Species 0.000 claims 1
- 210000002534 Adenoids Anatomy 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 210000004100 Adrenal Glands Anatomy 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 210000000013 Bile Ducts Anatomy 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 208000003362 Bronchogenic Carcinoma Diseases 0.000 claims 1
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 206010048832 Colon adenoma Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000007033 Dysgerminoma Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 210000003238 Esophagus Anatomy 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000005917 Exostosis Diseases 0.000 claims 1
- 208000007659 Fibroadenoma Diseases 0.000 claims 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 1
- 208000000527 Germinoma Diseases 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 206010018404 Glucagonoma Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 206010022498 Insulinoma Diseases 0.000 claims 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 210000001117 Keloid Anatomy 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 1
- 206010024627 Liposarcoma Diseases 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 210000002418 Meninges Anatomy 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000010492 Mucinous Cystadenocarcinoma Diseases 0.000 claims 1
- 206010028549 Myeloid leukaemia Diseases 0.000 claims 1
- 206010028576 Myeloproliferative disease Diseases 0.000 claims 1
- 208000009091 Myxoma Diseases 0.000 claims 1
- IKUYEYLZXGGCRD-ORAYPTAESA-N N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 claims 1
- 208000007538 Neurilemmoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 208000000035 Osteochondroma Diseases 0.000 claims 1
- 208000008798 Osteoma Diseases 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 208000005678 Rhabdomyoma Diseases 0.000 claims 1
- 206010039667 Schwannoma Diseases 0.000 claims 1
- 208000004548 Serous Cystadenocarcinoma Diseases 0.000 claims 1
- 208000000097 Sertoli-Leydig Cell Tumor Diseases 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- 210000002536 Stromal Cells Anatomy 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 208000001608 Teratocarcinoma Diseases 0.000 claims 1
- 210000001550 Testis Anatomy 0.000 claims 1
- 206010044412 Transitional cell carcinoma Diseases 0.000 claims 1
- 210000003708 Urethra Anatomy 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 210000001215 Vagina Anatomy 0.000 claims 1
- 208000009540 Villous Adenoma Diseases 0.000 claims 1
- 208000009311 Vipoma Diseases 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 210000003905 Vulva Anatomy 0.000 claims 1
- 206010048214 Xanthoma Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 1
- 201000003076 angiosarcoma Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000008975 bone inflammation disease Diseases 0.000 claims 1
- 201000003149 breast fibroadenoma Diseases 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 201000005217 chondroblastoma Diseases 0.000 claims 1
- 201000005262 chondroma Diseases 0.000 claims 1
- 201000009047 chordoma Diseases 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 claims 1
- 125000002944 cyanoaryl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000009051 embryonal carcinoma Diseases 0.000 claims 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 201000010934 exostosis Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 201000010915 glioblastoma multiforme Diseases 0.000 claims 1
- 235000009754 grape Nutrition 0.000 claims 1
- 235000012333 grape Nutrition 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000004593 malignant giant cell tumor Diseases 0.000 claims 1
- 201000000289 malignant teratoma Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims 1
- 201000000582 retinoblastoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000010208 seminoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775628P | 2018-12-05 | 2018-12-05 | |
| US62/775,628 | 2018-12-05 | ||
| PCT/US2019/064707 WO2020118066A1 (en) | 2018-12-05 | 2019-12-05 | Combination therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509724A JP2022509724A (ja) | 2022-01-24 |
| JPWO2020118066A5 true JPWO2020118066A5 (uk) | 2022-10-12 |
Family
ID=70973971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513314A Pending JP2022509724A (ja) | 2018-12-05 | 2019-12-05 | 組み合わせ療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220079947A1 (uk) |
| EP (1) | EP3890716A4 (uk) |
| JP (1) | JP2022509724A (uk) |
| KR (1) | KR20210113587A (uk) |
| CN (1) | CN113164418A (uk) |
| AU (1) | AU2019392683A1 (uk) |
| CA (1) | CA3112129A1 (uk) |
| EA (1) | EA202190630A1 (uk) |
| IL (1) | IL281348A (uk) |
| MX (2) | MX2021002804A (uk) |
| SG (1) | SG11202102357RA (uk) |
| WO (1) | WO2020118066A1 (uk) |
| ZA (1) | ZA202102016B (uk) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019340366A1 (en) * | 2018-09-10 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) * | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| US20220152026A1 (en) * | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| CN112341457A (zh) * | 2019-08-07 | 2021-02-09 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| CN112694475A (zh) * | 2019-10-23 | 2021-04-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
| CN112778301A (zh) * | 2019-11-07 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| TW202144349A (zh) * | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法 |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| EP4171557A1 (en) * | 2020-06-25 | 2023-05-03 | Tolremo Therapeutics AG | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer |
| WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
| CA3205008A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers |
| EP4284370A1 (en) * | 2021-01-29 | 2023-12-06 | Mirati Therapeutics, Inc. | Combination therapies |
| CN117813306A (zh) * | 2021-05-22 | 2024-04-02 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| TW202317100A (zh) * | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| WO2023168036A1 (en) * | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
| WO2024076672A1 (en) * | 2022-10-05 | 2024-04-11 | Amgen Inc. | Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof |
| WO2024081363A1 (en) * | 2022-10-12 | 2024-04-18 | Revolution Medicines, Inc. | Composition comprising a first ras inhibitor, second ras inhibitor and a shp2 inhibitor for use in the treatment of cancer |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613785B2 (en) | 1998-07-21 | 2003-09-02 | Smithkline Beecham Plc | Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| US20040043434A1 (en) | 2002-06-13 | 2004-03-04 | Gen-Sheng Feng | Shp-2 tyrosine phosphatase and embryonic stem cell differentiation |
| AU2003291254A1 (en) | 2002-11-05 | 2004-06-07 | Mount Sinai School Of Medicine Of New York University ; | Ptpn11 (shp-2) mutations and cancer |
| US20080058431A1 (en) | 2004-03-26 | 2008-03-06 | Gen-Sheng Feng | Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders |
| EP1728790A1 (en) | 2005-06-01 | 2006-12-06 | Max-Delbrück-Centrum Für Molekulare Medizin | Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases |
| US7547760B2 (en) | 2006-07-03 | 2009-06-16 | West Virginia University | Peptides and chemical compound for inhibition of SHP2 function |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| NL2008335A (en) | 2011-04-07 | 2012-10-09 | Asml Netherlands Bv | Lithographic apparatus, device manufacturing method, and method of correcting a mask. |
| HUE041499T2 (hu) | 2012-11-21 | 2019-05-28 | Janssen Biotech Inc | Bispecifikus EGFR/C-MET-ellenanyagok |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| US10532977B2 (en) | 2015-06-01 | 2020-01-14 | Indiana University Research And Technology Corporation | Small molecule inhibitors of protein tyrosine phosphatases and uses thereof |
| JP6718889B2 (ja) | 2015-06-19 | 2020-07-08 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| JP6878316B2 (ja) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| US10256121B2 (en) | 2015-07-06 | 2019-04-09 | Tokyo Electron Limited | Heated stage with variable thermal emissivity method and apparatus |
| US9932288B2 (en) | 2015-12-09 | 2018-04-03 | West Virginia University | Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent |
| AU2017266911B2 (en) | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| MA45189A (fr) | 2016-06-07 | 2019-04-10 | Jacobio Pharmaceuticals Co Ltd | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 |
| LT3710439T (lt) * | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| WO2020076723A1 (en) * | 2018-10-08 | 2020-04-16 | Revolution Medicines, Inc. | Shp2 inhibitor compositions for use in treating cancer |
-
2019
- 2019-12-05 SG SG11202102357RA patent/SG11202102357RA/en unknown
- 2019-12-05 US US17/275,181 patent/US20220079947A1/en active Pending
- 2019-12-05 EA EA202190630A patent/EA202190630A1/ru unknown
- 2019-12-05 CA CA3112129A patent/CA3112129A1/en active Pending
- 2019-12-05 CN CN201980077511.4A patent/CN113164418A/zh active Pending
- 2019-12-05 JP JP2021513314A patent/JP2022509724A/ja active Pending
- 2019-12-05 KR KR1020217008639A patent/KR20210113587A/ko unknown
- 2019-12-05 MX MX2021002804A patent/MX2021002804A/es unknown
- 2019-12-05 EP EP19893444.0A patent/EP3890716A4/en active Pending
- 2019-12-05 WO PCT/US2019/064707 patent/WO2020118066A1/en unknown
- 2019-12-05 AU AU2019392683A patent/AU2019392683A1/en active Pending
-
2021
- 2021-03-09 IL IL281348A patent/IL281348A/en unknown
- 2021-03-09 MX MX2024009727A patent/MX2024009727A/es unknown
- 2021-03-25 ZA ZA2021/02016A patent/ZA202102016B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020118066A5 (uk) | ||
| JP2019516718A5 (uk) | ||
| HRP20230377T1 (hr) | Inhibitori mutacije kras g12c | |
| AU2018200876C1 (en) | Inhibitors of histone demethylases | |
| KR102627266B1 (ko) | 암의 치료를 위한 2-헤테로아릴-3-옥소-2,3-디히드로피리다진-4-카르복스아미드 | |
| JPWO2020055761A5 (uk) | ||
| ES2255330T3 (es) | Espiroindolinas como antagonistas del receptor y5. | |
| ES2281565T3 (es) | Inhibidores de la integrasa de vih de tipo dihidroxipirimidina carboxamida. | |
| AU2018209667B2 (en) | JAK1 selective inhibitors | |
| JP2019504059A (ja) | Ｌｓｄ１阻害剤 | |
| BR112018067964B1 (pt) | Composto, composição farmacêutica que o compreende e uso do referido composto | |
| IL272941B (en) | Antiviral agents for viral hepatitis b | |
| MX2015002695A (es) | Derivados biciclicos fusionados de sulfamoilo y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| JPWO2020055760A5 (uk) | ||
| EA016829B1 (ru) | Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии | |
| SK14302000A3 (sk) | Deriváty indolyl-3-glyoxylovej kyseliny s protinádorovým účinkom | |
| CA3082855A1 (en) | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists | |
| JPWO2020055755A5 (uk) | ||
| CA3024482A1 (en) | Macrocyclic indole derivatives | |
| JP2010504351A5 (uk) | ||
| AU2008255815A1 (en) | Tetrahydroisoquinolin-1-one derivative or salt thereof | |
| JP2012524107A5 (uk) | ||
| JPWO2020055758A5 (uk) | ||
| ES2287466T3 (es) | Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa. | |
| JPWO2021061749A5 (uk) |